- Proteomics has the potential to revolutionize medicine in potentially the same way that genomics has. The traditional field looks primed for disruption and that effort could hit critical mass soon.
- Quantum-Si has set forth a business plan to utilize consumables as the primary driver of revenues and achieve a long-term goal of 70% margins.
- Significant revenues for Quantum-Si are still a few years off but next-generation technology is just now going through the final touches before commercialization.
- Quantum-Si looks to potentially be a leader in this burgeoning field, validation may take years to achieve however so this is a highly speculative stock and caution is warranted.
For further details see:
Proteomics May Be The Future Of Biotech, Quantum-Si Is A Potential Leader